Supernus Pharmaceuticals Inc (SUPN) : Bruce reduced its stake in Supernus Pharmaceuticals Inc by 11.78% during the most recent quarter end. The investment management company now holds a total of 224,581 shares of Supernus Pharmaceuticals Inc which is valued at $3.9 Million after selling 30,000 shares in Supernus Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Supernus Pharmaceuticals Inc makes up approximately 1.20% of Bruce’s portfolio.
Other Hedge Funds, Including , Alliancebernstein boosted its stake in SUPN in the latest quarter, The investment management firm added 15,730 additional shares and now holds a total of 71,870 shares of Supernus Pharmaceuticals Inc which is valued at $1.2 Million. Adams Street Partners sold out all of its stake in SUPN during the most recent quarter. The investment firm sold 151,117 shares of SUPN which is valued $2.6 Million. Tfs Capital added SUPN to its portfolio by purchasing 18,871 company shares during the most recent quarter which is valued at $326,091. Supernus Pharmaceuticals Inc makes up approx 0.05% of Tfs Capital’s portfolio.
Supernus Pharmaceuticals Inc opened for trading at $18.9 and hit $19.095 on the upside on Wednesday, eventually ending the session at $18.97, with a gain of 0.64% or 0.12 points. The heightened volatility saw the trading volume jump to 5,32,447 shares. Company has a market cap of $938 M.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.08 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.09. The company had revenue of $43.00 million for the quarter, compared to analysts expectations of $45.32 million. The company’s revenue was up 53.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.